SAREPTA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
SAREPTA THERAPEUTICS, INC. (SRPT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $8.82 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-02
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2013-12-31 was $344.00K, a 91.32% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2013-09-30 was $2.10M, a 110.06% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2013-06-30 was $1.60M.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2013-03-31 was $1.40M, a 500614.29% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $8.82M, a 84.57% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $57.16M, a 92.38% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $29.71M, a 144.53% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $12.15M, a 14.39% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $8.82M 10-K · filed 2026-03-02 | |||||
| 2024-12-31 | $57.16M 10-K · filed 2026-03-02 | |||||
| 2023-12-31 | $29.71M 10-K · filed 2026-03-02 | |||||
| 2022-12-31 | $12.15M 10-K · filed 2025-02-28 | |||||
| 2021-12-31 | $10.62M 10-K · filed 2024-02-28 | |||||
| 2020-12-31 | $144.75M 10-K · filed 2023-02-28 | |||||
| 2019-12-31 | $109.71M 10-K · filed 2022-03-01 | |||||
| 2018-12-31 | $158.94M 10-K · filed 2021-03-01 | |||||
| 2017-12-31 | $20.92M 10-K · filed 2020-02-26 | |||||
| 2016-12-31 | $30.61M 10-K · filed 2019-02-28 | |||||
| 2015-12-31 | $18.14M 10-K · filed 2018-03-01 | |||||
| 2014-12-31 | $1.50M 10-K · filed 2017-02-28 | |||||
| 2013-12-31 | $344.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $2.44M derived: sum of 2 quarters · filed 2016-02-25 | $4.04M derived: sum of 3 quarters · filed 2016-02-25 | $5.44M 10-K · filed 2016-02-25 | $5.40M 10-K · filed 2014-03-03 | |
| 2013-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $3.70M derived: sum of 2 quarters · filed 2013-11-12 | $5.10M 10-Q · filed 2013-11-12 | $9.06M derived: sum of 4 quarters · filed 2015-02-26 | ||
| 2013-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $3.00M 10-Q · filed 2013-08-08 | $6.96M derived: sum of 3 quarters · filed 2015-02-26 | $7.96M derived: sum of 4 quarters · filed 2015-02-26 | ||
| 2013-03-31 | $1.40M 10-Q · filed 2013-05-09 | $5.37M derived: sum of 2 quarters · filed 2015-02-26 | $6.37M derived: sum of 3 quarters · filed 2015-02-26 | $6.37M derived: sum of 4 quarters · filed 2015-02-26 | ||
| 2012-12-31 | $3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $4.96M derived: sum of 2 quarters · filed 2015-02-26 | $4.96M derived: sum of 3 quarters · filed 2015-02-26 | $4.96M 10-K · filed 2015-02-26 | $5.02M 10-K · filed 2013-03-15 | |
| 2012-09-30 | $999.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $999.72K derived: sum of 2 quarters · filed 2013-11-12 | $1.00M 10-Q · filed 2013-11-12 | $982.00K 10-Q · filed 2012-11-07 | $1.02M derived: sum of 4 quarters · filed 2014-03-03 | |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $280.00 10-Q · filed 2012-08-07 | $18.28K derived: sum of 3 quarters · filed 2014-03-03 | $30.28K derived: sum of 4 quarters · filed 2014-03-03 | ||
| 2012-03-31 | $280.00 10-Q · filed 2013-05-09 | $18.28K derived: sum of 2 quarters · filed 2014-03-03 | $30.28K derived: sum of 3 quarters · filed 2014-03-03 | |||
| 2011-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $30.00K derived: sum of 2 quarters · filed 2014-03-03 | $100.00K 10-K · filed 2014-03-03 | $82.00K 10-K · filed 2013-03-15 | ||
| 2011-09-30 | $12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $82.00K 10-Q · filed 2012-11-07 | ||||
| 2011-06-30 | $70.00K 10-Q · filed 2012-08-07 | |||||
| 2010-12-31 | $976.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |